# A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule

> **NCT05233657** · PHASE1 · UNKNOWN · sponsor: **Zhejiang Jingxin Pharmaceutical Co., Ltd.** · enrollment: 58 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** JX11502MA
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05233657
- **Lead sponsor:** Zhejiang Jingxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-04
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-02-28
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05233657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05233657, "A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05233657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*